Accéder au contenu
Merck

Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): a systematic review and meta-analysis.

Systematic reviews (2012-08-30)
Sanjin Alajbegovic, John W Sanders, Deborah E Atherly, Mark S Riddle
RÉSUMÉ

Recent developments related to a safe and effective nonabsorbable antibiotic, rifaximin, and identification of postinfectious irritable bowel syndrome as a frequent sequela call for a need to reconsider the value of primary prevention of traveler's diarrhea (TD) with antibiotics. Randomized, placebo-controlled, double-blind studies evaluating the effectiveness and safety of rifaximin or a fluoroquinolone chemoprophylaxis against TD were pooled using a random effects model and assessed for heterogeneity. The nine studies (four rifaximin and five fluoroquinolone) included resulted in pooled relative risk estimates of 0.33 (95% CI = 0.24-0.45, I2 = 3.1%) and 0.12 (95% CI = 0.07-0.20, I2 =0.0%), respectively. Similar rates of treatment emergent adverse events were found between antibiotic and placebo groups. This meta-analysis supports the effectiveness of antibiotics in preventing TD. However, further studies that include prevention of secondary chronic health outcomes among travelers to different geographic regions, and a formal risk-benefit analysis for antibiotic chemoprophylaxis, are needed.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Rifaximin
Référence
Conditionnement
Disponibilité
Prix
Quantité
Rifaximin, European Pharmacopoeia (EP) Reference Standard
Référence
Conditionnement
Disponibilité
Prix
Quantité
Rifaximin for system suitability, European Pharmacopoeia (EP) Reference Standard
Référence
Conditionnement
Disponibilité
Prix
Quantité
Supelco
Rifaximin, VETRANAL®, analytical standard
Référence
Conditionnement
Disponibilité
Prix
Quantité